Erica L. Mayer - Concepedia

Author

Erica L. Mayer

Also Known As

E Mayer, E. L. Mayer, E. Mayer, E.L. Mayer, Erica L Mayer, Erica L. Mayer, Erica Mayer, Erica L Mayer, Lenihan, Daniel J, Mayer, Erica

353

Publications

9.6K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Massachusetts General Hospital Brigham and Women's Hospital Beth Israel Deaconess Medical Center

About

Erica L. Mayer is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	36	3.9K
2	Health Sciences	5	5	122
3	Cell Biology	4	4	1.1K
4	Public Health	2	2	1.2K
5	Nursing	1	1	19

Erica L. Mayer

Publications

7.9K

Citations

H-Index

Page 1

	Year	Citations
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Saro H. Armenian, Christina Lacchetti, Ana Barac, Journal of Clinical Oncology Heart FailureAdult Cardiac SurgeryAmerican SocietyCardiac DysfunctionPreventive Cardiology	2017	1.2K
Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL Ramesh A. Shivdasani, Erica L. Mayer, Stuart H. Orkin Nature Hematological MalignancyBlood FormationMedicineMalignant Blood DisorderHematology	1995	953
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer Lisa A. Carey, Hope S. Rugo, P. Kelly Marcom, Journal of Clinical Oncology	2012	489
Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer Ann H. Partridge, Andrea LaFountain, Erica L. Mayer, Journal of Clinical Oncology	2008	483
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer Steven J. Isakoff, Erica L. Mayer, Lei He, Journal of Clinical Oncology	2015	412
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer, The Lancet Oncology Epithelial Ovarian CancerMedicinePharmacologyGynecologyPharmacotherapy	2019	258
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study Erica L. Mayer, Amylou C. Dueck, Miguel Martín, The Lancet Oncology Interim AnalysisEndocrine OncologyBreast OncologyOncologyEarly Breast Cancer	2021	250
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance) Hope S. Rugo, William T. Barry, Alvaro Moreno‐Aspitia, Journal of Clinical Oncology	2015	226
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) Michael Gnant, Amylou C. Dueck, Sophie Frantal, Journal of Clinical Oncology	2021	220
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology Don S. Dizon, Lada Krilov, Ezra E.W. Cohen, Journal of Clinical Oncology MedicineCancer ManagementPathologyAmerican SocietyClinical Oncology	2016	212

Page 1